1 |
刘慧敏,周乾宇,贾善群,等.2004-2018年中国肺癌死亡趋势分析及预测[J].中国预防医学杂志,2021,22(12):913-919.
|
2 |
THAI A A, SOLOMON B J, SEQUIST L V, et al. Lung cancer[J]. Lancet, 2021, 398(10299):535-554.
|
3 |
GANTI A K, KLEIN A B, COTARLA I,et al. Update of incidence,prevalence,survival,and initial treatment in patients with non-small cell lung cancer in the US[J]. JAMA Oncol, 2021,7(12):1824-1832.
|
4 |
KOEGELENBERG C F N, SHAW J A, IRUSEN E M, et al. Contemporary best practice in the management of malignant pleural effusion [J]. Ther Adv Respir Dis, 2018,12:1-13.
|
5 |
尹文琤,张华,顾阳春, 等.76例初诊EGFR突变阳性合并胸腔积液肺腺癌患者的临床特征及预后分析:一项单中心、回顾性研究[J].中国肺癌杂志,2022,25(3):156-166.
|
6 |
MANSSON C T, VAD-NIELSEN J, MELDGAARD P, et al. EGFR transcription in non-small-cell lung cancer tumours can be revealed in ctDNA by cell-free chromatin immunoprecipitation (cfChIP) [J]. Mol Oncol, 2021,15(11):2868-2876.
|
7 |
中华医学会病理学分会细胞学组. 非小细胞肺癌恶性浆膜腔积液分子病理检测中国专家共识[J]. 中华病理学杂志, 2022,51(12):1198-1204.
|
8 |
陆如建,褚红军,尤庆生,等. EGFR基因突变及ERCC1、RRM1表达在非小细胞肺癌精准化治疗中的应用价值[J]. 交通医学, 2017,31(2):115-120.
|
9 |
唐珊珊,李莉,袁双虎. EGFR 19/21位点突变与597例非小细胞肺癌患者中发生脑转移的关联分析[J]. 中华肿瘤防治杂志,2019,26(10):724-727.
|
10 |
孔君,杨雪,孔辉,等. 2394例肺腺癌患者EGFR及ALK驱动基因分析[J]. 南京医科大学学报(自然科学版),2020,40(5):675-680,719.
|
11 |
ALIKHANYAN K, CHEN Y, KRAUT S, et al. Targeting alveolar macrophages shows better treatment response than deletion of interstitial macrophages in EGFR mutant lung adenocarcinoma[J]. Immun Inflamm Dis, 2020,8(2):181-187.
|
12 |
CHARPIDOU A, BLATZA D, ANAGNOSTOU V,et al. EGFR mutations in non-small cell lung cancer-clinical implications[J]. In Vivo, 2008,22(4): 529-536.
|
13 |
SHI Y, ZHOU C, HU C P,et al. A prospective,molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology ( PIONEER) [J]. J Thocac Oncol, 2014,9(2): 154-162.
|
14 |
ZHOU J, SONG X B, HE H,et al . Prevalence and clinical profile of EGFR mutation in non-small cell lung carcinoma patients in southwest china[J]. Asian Pac J Cancer Prev,2016,17(3): 965-971.
|
15 |
LIM J U, YEO C D, RHEE C K, et al. Chronic Obstructive Pulmonary Disease-Related Non-Small-Cell Lung Cancer Exhibits a Low Prevalence of EGFR and ALK Driver Mutations[J]. PLoS One, 2015,10(11):e0142306.
|
16 |
李龙,刘海潮,胡振红,等. 慢性阻塞性肺疾病合并非小细胞肺癌患者EGFR和EML4-ALK突变特点分析[J]. 华南国防医学杂志, 2021,35(8):549-552.
|
17 |
HOUGHTON A M, MOUDED M, SHAPIRO S D. Common origins of lung cancer and COPD[J]. Nat Med,2008,14:1023-1024.
|
18 |
王艳,张申众,袁秀敏,等. EGFR基因19或21外显子突变非小细胞肺癌的临床病理特征及靶向治疗效果[J]. 实用癌症杂志, 2019,34(5):759-762.
|
19 |
刘仁旺,刘京豪,李昕,等. EGFR 19和21外显子突变肺癌患者的临床特征比较和预后分析[J].中国肺癌杂志, 2014,17(11):804-811.
|
20 |
CHEN Z, ZHANG J, HUANG K, et al. Comparison of clinicopathologic characteristics between patients with EGFR exon 19 deletion and EGFR L858R mutation in lung cancer[J]. Int J Clin Exp Pathol, 2018,11(9):4644-4649.
|
21 |
He Y, LI S, REN S, et al. Impact of family history of cancer on the incidence of mutation in epidermal growth factor receptor gene in non-small cell lung cancer patients[J]. Lung Cancer, 2013,81:162-166.
|
22 |
ZHAO F N, ZHAO Y Q, HAN L Z,et al .Clinicoradiological features associated with epidermal growth factor receptor exon 19 and 21 mutation in lung adenocarcinoma[J]. Clin Radiol,2018,74(1): 80.e7-80.e17.
|
23 |
LU R L, HU C P, YANG H P,et al. Biological characteristics and epidermal growth factor receptor tyrosine kinase inhibitors efficacy of EGFR mutation and its subtypes in lung adenocarcinom [J]. Pathol & Oncol Res, 2014,20(2): 445-451.
|
24 |
房延凤,马李杰,刘雁声,等. 非小细胞肺癌E19-Del、L858R突变临床特征分析[J]. 中华肺部疾病杂志(电子版),2020,13(2):164-168.
|